X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Zepbound (tirzepatide) injection acts by activating both, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors. It is being evaluated for obstructive sleep apnea & obesity.
Lead Product(s): Tirzepatide
Therapeutic Area: Sleep Product Name: Zepbound
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
The funding will be used to support Phase II clinical development of BioAge’s lead compound BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: BGE-105
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sofinnova Investments
Deal Size: $170.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing February 13, 2024
Details:
Zepbound™ (tirzepatide) injection is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Lead Product(s): Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: Zepbound
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2023
Details:
As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: BGE-105
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 26, 2023
Details:
VERU-024 (enobosarm), a selective androgen receptor modulator, into a Phase 2b clinical trial in combination with semaglutide to evaluate the efficacy and the safety of enobosarm to further increase fat loss.
Lead Product(s): Enobosarm,Abemaciclib,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist, which enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner. it is being investigated for weight loss in adults with obesity and type 2 diabetes.
Lead Product(s): Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: Mounjaro
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist, which enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner. it is being investigated for weight loss in adults with obesity and type 2 diabetes.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: Mounjaro
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist, which enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: Mounjaro
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Mitsubishi Tanabe Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single novel molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones.
Lead Product(s): Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The secondary objectives presented today at ADA compared the effects of Mounjaro (tirzepatide) 15 mg to placebo and to injectable semaglutide 1 mg on energy intake, appetite and body composition in adults with type 2 diabetes as measured by change from baseline.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: Mounjaro
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Mounjaro (tirzepatide) met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimands.
Lead Product(s): Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: Mounjaro
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
Based on the results, the pharmacology of LY3298176 (tirzepatide) translates from preclinical to clinical studies. LY3298176 has the potential to deliver clinically meaningful improvement in glycaemic control and body weight.
Lead Product(s): Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Mounjaro (tirzepatide) delivered superior and consistent A1C reductions against comparators throughout SURPASS program, which was designed to assess Mounjaro's efficacy and safety in a broad range of adults with type 2 diabetes who could be treated in clinical practice.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: Mounjaro
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2022
Details:
For efficacy estimand, participants taking tirzepatide achieved average weight reduction of 16.0%, 21.4%, and 22.5%, compared to placebo. Additionally, 89% and 96% of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of those taking placebo.
Lead Product(s): Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Tirzepatide is novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist that integrates actions of both incretins into single molecule, representing new class of medicines being studied for treatment of type 2 diabetes.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
SURPASS-2 and SURPASS-3 compared the efficacy and safety of the same three doses of tirzepatide to injectable semaglutide 1 mg and insulin degludec, respectively.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
In an additional secondary endpoint, tirzepatide led to improvements in the change in two-hour post-meal glucose values from baseline from self-monitored blood glucose data.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2021
Details:
The overall safety profile of tirzepatide was similar to the well-established glucagon-like peptide-1 (GLP-1) receptor agonist class. Across all treatment arms, the most commonly reported adverse events were gastrointestinal-related.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Details:
The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 13,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to those taking semaglutide 1 mg.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
Tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes in Eli Lilly's SURPASS-3 and SURPASS-5 phase 3 clinical trials after 52 weeks and 40 weeks.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2021
Details:
Using the efficacy estimandi, the highest dose of tirzepatide led to an A1C reduction of 2.07 percent and reduced body weight by 9.5 kg (11.0 percent). More than half (51.7 percent) of participants in the treatment arm achieved an A1C less than 5.7 percent.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Eli Lilly and Company will conduct a webcast to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
The study will assess both non-inferiority and superiority of tirzepatide in a head-to-head trial against Trulicity® (dulaglutide) 1.5 mg – the market leading GLP-1 receptor agonist.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
